A clinical trial in subjects who suffer from hay fever to see the effects of the study medication, SB-705498, when taken on its own or in conjunction with a background therapy, Fluticasone Propionate, on the symptoms triggered by an allergen challenge chamber session.

Registry ID
EUCTR2011-000115-11
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
GlaxoSmithKline Research and Development Ltd
Start date
2011-04-19
Completion date
2011-07-07
Last update
2026-08-16

Conditions

Summary

Effect of 8 day treatment with intranasal SB-705498 on nasal symptoms elicited by an allergen chamber challenge in subjects with allergic rhinitis when co-administered with FP, compared to FP alone. Effect of 8 day treatment with intranasal SB-705498 on nasal symptoms elicited by anallergen chamber challenge in subjects with allergic rhinitis compared to placebo.

Locations

View on source registry